NCT07171983View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

January 22, 2026

Primary Completion Date

June 28, 2027

Study Completion Date

August 25, 2027

Conditions
Rheumatoid Arthritis
Interventions
DRUG

BMS-986454

Specified dose on specified days

OTHER

Placebo

Specified dose on specified days

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY